Shares of Xenon Pharmaceuticals Inc. XENE fell 1.6% premarket on Monday after the neurology-focused company released new data from a clinical trial of its lead asset, an experimental depression treatment.
The treatment, XEN1101, produced a clinically meaningful but not statistically significant change in the depression rating scale that served as the study’s primary endpoint, Xenon said in a release. The trial involved 168 patients with moderate to severe major depressive disorder.
XEN1101…
Master your money.
Subscribe to MarketWatch.
Get this article and all of MarketWatch.
Access from any device. Anywhere. Anytime.
Subscribe Now
Already a subscriber?
Log In
Read the full article here
